Document Classification

Section Type: RESULTS

Text: Among patients with below the median plasma concentrations of galectin-3 (19. 0 ng/mL), those assigned to rosuvastatin had a lower primary event rate [hazard ratio (HR) 0. 65 ; 95 % confidence interval (CI), 0. 46-0. 92 ; P = 0. 014], lower total mortality (HR 0. 70 ; 95 % CI, 0. 50-0. 98 ; P = 0. 038), and lower event rate of all-cause mortality and HF hospitalizations (HR 0. 72 ; 95 % CI, 0. 54-0. 98 ; P = 0. 017) compared with placebo, but no benefit was observed in patients with higher levels of galectin-3.